Janus Henderson Group’s Zomedica Corp. ZOM Stock Holding History

Janus Henderson Group’s Portfolio ZOM Stock Details ZOM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-177,068	Closed	-$60K	–	2767
2022 Q1	$60K	Hold	177,068	–	–	﹤0.01%	2614
2021 Q4	$55K	Buy	177,068 +88,139	+99%	+$39.7K	﹤0.01%	2537
2021 Q3	$46K	Buy	+88,929	New	+$52.5K	﹤0.01%	2178

Other funds holding ZOM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BBHC

Brown Brothers Harriman & Co New York $18.6B AUM 15.81% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

PWMG

Pinnacle Wealth Management Group Plymouth, Michigan $214M AUM 20.07% 1-Year Est. Return

Janus Henderson Group's ZOM Position: Q2 2022 in Review

Janus Henderson Group sold out of Zomedica Corp. (ZOM) in Q2 2022, closing a stake of 177,068 shares — an estimated $60K sold.

Janus Henderson Group first reported a position in ZOM in Q3 2021 and held it in 3 quarters. The position peaked at $60K in Q1 2022. 97 funds tracked by Wall St. Rank hold ZOM as of Q2 2022.

Janus Henderson Group reported no remaining Zomedica Corp. position as of Q2 2022 after selling out during the quarter.
Janus Henderson Group sold 177,068 Zomedica Corp. shares in Q2 2022, an estimated $60K.
Janus Henderson Group first reported a position in Zomedica Corp. in Q3 2021 and held it in 3 quarters.
Janus Henderson Group's Zomedica Corp. position peaked at $60K in Q1 2022.
97 funds tracked by Wall St. Rank held Zomedica Corp. as of Q2 2022.

Based on Janus Henderson Group's 13F filing for Q2 2022, filed 15 Aug 2022.